Leerink Partners Maintains Bullish Rating on Evommune
Leerink Partners analyst Thomas Smith has reaffirmed a bullish rating and a $22 price target for Evommune, Inc. (EVMN).
Stocks · News reference
Filed: 2026-11-17 AccNo: 0001193125-26-465600 Size: 181 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Leerink Partners analyst Thomas Smith has reaffirmed a bullish rating and a $22 price target for Evommune, Inc. (EVMN).
Needham & Company analyst Serge Belanger has maintained a 'Buy' rating on Evommune, Inc. while lowering the price target from $28 to $25.
Evommune, Inc. announced its financial results for the third quarter of 2026, reporting a GAAP EPS of -$0.85, which beat analyst consensus estimates by $0.01.
Evommune, Inc. announced that its management team will participate in upcoming investor conferences in November 2026.
Evommune, Inc. announced a pre-recorded webcast to discuss its investigational oral VAV1-directed molecular glue degrader, EVO570, and its broader immunology portfolio.